High-Dose Sulbactam Dosing Map Offers New Weapon Against Drug-Resistant Superbug

One of the world’s most feared hospital superbugs may have met its match in an old antibiotic given in a new way. A team of Thai researchers has completed one of the most detailed studies to date of how the drug sulbactam behaves in the bodies of critically ill patients battling carbapenem-resistant Acinetobacter baumannii, or CRAB, an infection so stubborn that physicians often run out of effective options. Their findings, published in BMC Infectious Diseases, provide a practical dosing blueprint that could help clinicians worldwide squeeze maximum killing power from a drug they already have on the shelf.

CRAB has earned a place on the World Health Organization’s list of priority pathogens for good reason. The bacterium thrives in hospitals, colonizes ventilators and catheters, and shrugs off carbapenems, the last-line antibiotics that once served as a reliable backstop. Sulbactam, a beta-lactam compound traditionally paired with ampicillin, has re-emerged as a surprising ally because it retains intrinsic activity against A. baumannii even at high concentrations. The catch is that no one has been entirely sure how much sulbactam critically ill patients actually need, or how their changing kidney function alters the drug’s journey through the body.

To answer those questions, researchers led by Nadia Cheh-Oh of Prince of Songkla University and Wichai Santimaleeworagun of Silpakorn University conducted a prospective pharmacokinetic study at Phramongkutklao Hospital in Bangkok between January 2021 and May 2023. They enrolled 55 patients suffering from pneumonia or bloodstream infections caused by CRAB and collected 268 blood samples over seven days of treatment. Each patient received daily sulbactam doses of 9 to 12 grams, adjusted for kidney function, a far cry from the modest amounts the drug delivers when used merely as a beta-lactamase inhibitor in older combination products.

The team then turned to population pharmacokinetic modeling, a statistical technique that uses sparse blood samples from many individuals to build a mathematical picture of how a drug moves through the body. Using the NONMEM software platform, version 7.5.1, they tested competing structural models and settled on a two-compartment model with first-order elimination, achieving an objective function value of 2377. In plain terms, the model describes sulbactam as shuttling between a central compartment, essentially the bloodstream and well-perfused organs, and a peripheral compartment representing deeper tissues, before being cleared primarily by the kidneys.

The fitted parameters tell an important story. Typical clearance came out at 3.17 liters per hour, the central compartment volume at 14.98 liters, the peripheral volume at 9.21 liters, and intercompartmental clearance at 4.84 liters per hour. When the researchers tested patient characteristics as potential covariates, creatinine clearance, a standard measure of kidney filtration, emerged as the only significant predictor of both drug clearance and central compartment volume. That finding matters enormously in the intensive care unit, where kidney function can swing dramatically from day to day and where patients with augmented renal clearance may flush antibiotics out of their systems faster than standard regimens can replenish them.

With the model in hand, the researchers ran Monte Carlo simulations using Crystal Ball software to ask a deceptively simple question: which dosing regimens give patients the best odds of keeping free sulbactam concentrations above the minimum inhibitory concentration, or MIC, of their infecting bacteria for at least half, three-quarters, or all of the dosing interval? This metric, known as fT greater than MIC, is the pharmacodynamic driver for beta-lactam antibiotics, meaning that time above the threshold, not peak concentration, determines bacterial kill. The simulations calculated the probability of target attainment, or PTA, across thousands of virtual patients with varying kidney function.

The results offer clear guidance. For patients with normal kidney function, a daily dose of 12 grams proved sufficient. Against pathogens with an MIC of 32 micrograms per milliliter, a demanding threshold that reflects the high resistance levels seen in CRAB, an extended infusion of 4 grams every eight hours infused over four hours achieved a probability of target attainment above 80 percent for the 50 percent fT greater than MIC target in patients with creatinine clearance between 61 and 120 milliliters per minute. Even better, a continuous infusion delivering 12 grams per day pushed the probability above 90 percent across all three pharmacodynamic targets, including the most stringent requirement that concentrations stay above the MIC for the entire dosing period.

Those numbers carry real clinical weight. Extended and continuous infusions have become standard thinking in modern antibiotic stewardship because beta-lactams work best when concentrations hover steadily above the bacterial kill threshold rather than spiking and crashing. By demonstrating that a full 12 grams per day can be delivered safely enough to hit even the 100 percent fT greater than MIC target in most patients, the study gives clinicians a defensible strategy for the sickest CRAB cases, particularly when laboratory susceptibility results suggest a high MIC and every percentage point of time above threshold could decide whether the infection clears.

The researchers emphasize that their dosing framework is especially valuable where therapeutic drug monitoring is unavailable. Measuring antibiotic levels directly in patient blood remains a luxury in many hospitals, particularly in the low- and middle-income countries where CRAB hits hardest. A validated population model combined with Monte Carlo simulation allows clinicians to estimate exposure probabilities from readily available data, chiefly creatinine clearance and the pathogen’s MIC, and to adjust doses accordingly. The study also reinforces a recurring theme in critical care pharmacology: renal function is the master variable for hydrophilic antibiotics, and one-size-fits-all dosing leaves some patients dangerously underexposed while exposing others to potential toxicity.

Limitations accompany any single-center study of 55 patients, and the model will need validation in other populations and settings before guidelines change wholesale. Still, the work represents a meaningful step in the global fight against antimicrobial resistance, demonstrating how careful pharmacometric analysis can resurrect older drugs and optimize them for the era of extreme drug resistance. As CRAB continues to stalk intensive care units around the world, the humble sulbactam molecule, dosed aggressively and intelligently, may buy critically ill patients the time their immune systems need to win.

Subject of Research: Population pharmacokinetics and optimized dosing of high-dose sulbactam for carbapenem-resistant Acinetobacter baumannii infection

Article Title: High-dose sulbactam population pharmacokinetics in patients with severe carbapenem-resistant Acinetobacter baumannii infection

Article References: High-dose sulbactam population pharmacokinetics in patients with severe carbapenem-resistant Acinetobacter baumannii infection. (n.d.). https://doi.org/10.1186/s12879-026-14426-9

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14426-9

Keywords: sulbactam, carbapenem-resistant Acinetobacter baumannii, pharmacokinetics, antimicrobial resistance, Monte Carlo simulation, creatinine clearance, minimum inhibitory concentration, continuous infusion, CRAB, antibiotic dosing, BMC Infectious Diseases, critical care